I have said many times that one of the more important issues facing our use of Provenge is when to start it and how to sequence this treatment with the other newly approved agents that have recently become available for men with advanced prostate cancer. There is occasional conversation that Provenge is already antiquated due [...]
There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]
Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]
